[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Venture Life Group Plc LSE:VLG London Ordinary Share GB00BFPM8908 ORD 0.3P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.75 -1.57% 47.00 47.00 48.50 47.75 47.75 47.75 60,604 16:35:15
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 30.1 3.3 2.7 17.2 59

Venture Life Share Discussion Threads

Showing 35926 to 35949 of 36025 messages
Chat Pages: 1441  1440  1439  1438  1437  1436  1435  1434  1433  1432  1431  1430  Older
DateSubjectAuthorDiscuss
13/8/2021
07:25
So, its all going well apart from the bits that are ging badly. No meaningful numbers supplied. That share placing is looking like a fantastic decision for the directors.
shanklin
13/8/2021
07:23
Well i was not expecting that. We certainly won’t be getting an earnings upgrade and now it looks like BBI will have to make up the shortfall.
rimau1
12/8/2021
15:04
Was there two more acquisitions flagged at the time of the placing... Are these still expected ?
thedudie
12/8/2021
14:45
Indeed, maybe the paper copy of IC tomorrow will see a little squeeze on?!
qs99
12/8/2021
14:08
Good to see buying coming in at the full 100p offer price now.
rivaldo
11/8/2021
08:41
Thanks Riv
qs99
11/8/2021
08:08
Indeed - and still lots of upside to ST's 130p target price. Investors are "guaranteed some hefty earnings upgrades" here..... Https://www.investorschronicle.co.uk/ideas/2021/08/10/exploiting-an-earning-upgrade-opportunity/
rivaldo
11/8/2021
07:40
Who could this be in the IC .... ? "Exploiting an earnings upgrade opportunity A developer, manufacturer and distributor of products for the self-care market has made two earnings accretive acquisitions this summer and a forthcoming pre-close trading statement is set to prompt earnings upgrades. Simon Thompson reports".
effortless cool
11/8/2021
07:39
Nice update from Mr T this morning, he also expects a TU in the coming weeks accompanied by earnings upgrades to reflect the recent acquisitions. Should help VLG kick on this morning.
rimau1
09/8/2021
23:01
Amala Foods: Looking tasty, launching plant based meat alternative foods for rapidly growing Asian market, backed by serial entrepreneur Archi Rodriguez, could 100x bag. hTTps://uk.advfn.com/cmn/fbb/thread.php3?id=48485421
sharetalk
06/8/2021
13:25
And as you say, no TU as yet, probs wanted this deal out of the way, so maybe we will get one ahead of the interims? DYOR
qs99
06/8/2021
13:24
Hardly any stock at all it seems....should get a nice squeeze on IMO next week if ST picks this up, any broker upgrades? DYOR CHeers QS99
qs99
06/8/2021
12:19
Great to see Vulcan finally close. I wonder if they held off on the TU until it closed and so we may well get a TU next week as well as an ST update? I had a cheeky top up, you can still buy at the placing price. Hello operational leverage, welcome to VLG!!
rimau1
06/8/2021
10:26
Good summary Riv and yes expect ST to upgrade following this deal IMO/DYOR
qs99
06/8/2021
10:24
Cheers EC - so not only is the consideration nicely reduced, but it would seem that VLG are now paying just £4.7m for a baseline £1.2m EBITDA, which could rise substantially with synergies, partnerships etc. Looks very, very good.
rivaldo
06/8/2021
08:47
This is what Simon Thompson had to say after the previous acquisition back in June. I would expect an update next week and an increase in his target price following this morning's news. Aim-traded Venture Life (VLG:92p), a developer, manufacturer and distributor of products for the self-care market, has announced the £36m acquisition of BBI Healthcare, a highly profitable global market leading women's health and diabetes/energy management company. BBI’s key brands are Balance Activ, the leading UK brand for the treatment of bacterial vaginosis; Glucogel, the number one glucose gel prescribed in the UK for hypoglycemia; and Lift, a range of glucose gels, shots and chewable tablets. BBI owns all the IP associated with the brands which are sold or partnered across 27 countries. In addition, BBI has developed a new women’s health product and signed a distribution agreement with an [undisclosed] international partner for the new product to be launched under their own well-known brand in Europe, China and USA. This is the first acquisition since Venture raised £34m placing and £2m open offer at 90p a share last November to fund its acquisition strategy. BBI reported adjusted cash profit of £2.6m on £10.2m revenue in 2020, and profits will be materially higher this year after taking account of product initiatives and cost synergies. In fact, the £36m acquisition has been priced on a “high single-digit cash profit multiple for 2021”, implying cash profit will grow by at least 50 per cent. Moreover, there are multiple strategic benefits that will boost BBI’s profits in 2022 including cross-selling opportunities between Venture’s existing customer base, marketing BBI’s products through its enlarged distribution network, and utilising BBI’s manufacturing facilities in Sweden. They are currently running at 20 per cent capacity, thus offering a material opportunity to generate additional revenue by ramping up production. Although the acquisition leaves Venture in a slightly positive net cash position, the group is putting in place a revolving credit facility to enable further acquisitions. Management expect to update the market soon on other deals in the pipeline including Project Vulcan, a company focused on oncology support therapies to treat the dermatological and oral side-effects of cancer treatments. Venture’s directors see an opportunity to increase the distribution of the brands' products into more territories using its own network of local partners, along with new partners. In 2019, Vulcan generated £3.5m in net sales and an estimated cash profit excess of £1.2m. The £5.5m consideration equates to 4.5 times cash profit. The point is that although housebroker Cenkos Securities is holding fire on upgrading its estimates for now, then we are guaranteed some hefty uplifts later this summer. Analysts currently expect Venture’s cash profit (pre-BBI acquisition) to increase 14 per cent to £7m on 10 per cent higher revenue of £33.3m. However, a six-month contribution in 2021 from BBI would increase Venture’s cash profit to £9m, implying 50 per cent year-on-year growth. On an annualised basis, group cash profit run rate will be closer to £11m, or 83 per cent higher than in 2020. This implies Venture is being valued on a multiple of 10 times annualised cash profit to enterprise valuation, a modest rating for a company that is set to generate further revenue and cost benefits from BBI and has a cracking track record of integrating acquisitions. The key reason why the shares have doubled since I initiated coverage, at 45p, in my May 2019 Alpha Report is management’s ability to outperform. The BBI acquisition and imminent news of further bolt-on deals are set to support further earnings upgrades, and that’s simply not being priced in. I maintain my 130p target price. BUY.
sev22
06/8/2021
08:42
EC 1066 - nice analysis. And I guess we wanted to see 2020 numbers before negotiating reduced price - hence the delay in doing the deal. If FX has worked in our favour, then thats a bonus. I'm happy with that.
melody9999
06/8/2021
08:17
https://www.proactiveinvestors.co.uk/companies/news/957030/venture-life-snaps-up-products-package-from-swiss-oncology-firm-957030.html
sev22
06/8/2021
07:31
So Project Vulcan finally concludes! This is what they said about it back in November 2020, when they raised the funds to do this deal: "In 2019, Vulcan generated £3.5 million in net sales and an estimated EBITDA in excess of £1.2 million. The Directors expect the consideration payable for Vulcan to be approximately £5.5 million on a cash free, debt free basis". So £3.5m revenue might be considered the normal run rate, as opposed to £2.5m last year. They are paying about £0.8m less than originally mooted, so at least they have managed to negotiate the price down a bit over the last 9 months, although about a third of the saving is FX. Target A and Target B remain outstanding: "Target A" is a heritage brand in the UK and EU within the oral care market. Its product can be manufactured internally by the Group. The Directors see an opportunity to expand its niche customer base in the UK and internationally through the Group's distribution network. In the year ended 31 December 2019, Target A generated approximately £3.0 million in estimated net sales, with a margin in excess of 30 per cent. The Directors expect that the consideration payable for Target A would be in the region of £5 million". "Target B" is a well-known heritage dermatological brand and is widely marketed in the UK. Its products are capable of being manufactured internally by the Group. As with Vulcan and Target A, the Directors have identified an opportunity to expand the product's distribution into global markets through the Group's network. The Directors consider that the Target B's valuation is in the approximate range of £15 to 20 million".
effortless cool
06/8/2021
07:17
Looks like a very astute deal IMO. Good timing, decent products with high gross margin, immediately enhancing, attractive multiple paid, already known to VLG so ease of transition, possible other products to come out of this Lovely job, well done management. GLA and GWA Cheers QS99
qs99
06/8/2021
07:11
Looks like a very good acquisition of three oncology brands, two of which VLG already manufacture. Immediately earnings-enhancing given £1.3m historic gross profit for a £4.7m consideration - and that was in the first pandemic year, so there should be a sharp increase in profits from here. Especially with the various synergies and growth/partnering strategies which VLG can bring to the party: Https://uk.advfn.com/stock-market/london/venture-life-VLG/share-news/Venture-Life-Group-PLC-Acquisition-of-Oncology-Sup/85772749
rivaldo
30/7/2021
14:30
Asian markets had a down day that may have sparked a bit of a sell off, given investors are impatiently waiting for more takeover news. Lots of smallish sells, but I notice 3 x 50k + a 60k buys between 9-10. Hopefully the larger trades buyer/s is/are smarter than the small trade sellers.
red ninja
30/7/2021
13:41
Quiet and slipping. Any views?
qs99
24/7/2021
13:25
are we due a trading update next week ? Its all gone very quiet so hopefully primed for a burst of activity (upwards hopefully!)
rachael777
Chat Pages: 1441  1440  1439  1438  1437  1436  1435  1434  1433  1432  1431  1430  Older
ADVFN Advertorial
Your Recent History
LSE
VLG
Venture Li..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211025 00:39:38